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Background: Chronic obstructive pulmonary disease (COPD) is a progressive disorder charac-
terized by an inflammatory response to cigarette smoke. A disorder in immune regulation
contributing to the pathogenesis of COPD has been suggested, however, little is known about
the involvement of CD4 þ T cells. To determine the distribution of different CD4þ T cell subsets
in patients with COPD, current smokers without COPD (CS) and healthy subjects (HS), and its
correlation with pulmonary function.
Methods: Th1, Th2, Th17 and Treg, subsets, were quantified by flow cytometry in peripheral
blood (PB) of 39 patients with COPD, 14 CS and 15 HS. Correlations were assessed with Spear-
man’s rank test. The association between Th17 and lung function was evaluated with a multi-
variate logistic regression analysis.
Results: An increase of Th17 cells (median 9.7% range 0.8e22.5%) was observed in patients
with COPD compared with CS (median 2.8% range 0.8e10.6) and HS (median 0.6% range 0.4
e1%, p < 0.0001). Th1 and Tregs subsets were also increased in COPD and CS compared to
HS. Inverse correlations were found between Th17 with FEV1%p r Z 0.57 and with FEV1/
FVC r Z 0.60, (p < 0.0001 for both comparison). In addition, increase of Th17 predicted
the presence [OR 1.76 (CI 95% 1.25e2.49, p Z 0.001)] and severity of airflow limitation [OR
1.13 (CI95% 1.02e1.25, p Z 0.02)].5 54871742; fax: þ52 55 54871742.
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Age-yrs
Gender, M/F
Tobacco, pack/yrs
FEV1 ml
FEV1 % predicted
FVC ml
FVC % predicted
FEV1/FVC
Definition of abbreviations: CS Z Cu
*ANOVA One way Analysis.Conclusions: The increase of Th17 response and the lost of balance between CD4þ T cell
subsets, suggest a lack of regulation of the systemic inflammatory response that may
contribute to pathogenesis in COPD patients.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a progres-
sive, largely irreversible condition characterized by airflow
limitation.1 Cigarette smoking is the main risk factor for the
development of COPD.2 Tobacco smoking elicits an inflam-
matory response in the lungs of all smokers, but in those who
develop COPD it is enhanced and fails to resolve after cessa-
tion of smoking, which suggests that smokers who develop
COPD have an abnormal regulation of the inflammatory
response in the lungs. 3 However, the relationship between
the inflammatory response in the lungs and the accelerated
decline in forced expiratory volume in 1 s (FEV1), which
characterizes this disease, is far from clear. In this sense, by
considering that COPD is associated with an abnormal
inflammatory response in the lungs, Agustı´ et al., suggested
that excessive inflammation is the key to susceptibility, sup-
porting the notion that COPD has an autoimmune compo-
nent.4 Inflammation in COPD shows an increase in the total
number of T cells in lung parenchyma, and peripheral and
central airways.5 CD4þ and predominantly CD8þ T cells infil-
trates in lung tissue of COPD patients exhibit either a Th1 or
a Th2 phenotype characterized by expression of interferon-
gamma (IFN-g) or interleukin-4 (IL-4).6 Several groups have
proposed that the alveolar tissue destruction observed in
emphysema represents anautoimmunedisorder implicatingT
cells as central to disease pathogenesis.7e11 However, impli-
cation of T CD4þ cells subsets involved in the inflammatory
responsemaydeterminewhether polarization of one of these
cells is involved in perpetuating the inflammatory process
that leads to the development of this disease.
IL-17A and IL-17F, two members of IL-17 family of
cytokines, have been shown to induce neutrophilic airway
inflammation by stimulation of neutrophil chemotaxis and
mucin gene expression by bronchial epithelial cells.12,13
Given the recent identification of Th17 cells, as a distinct
effectors T cell subset, secreting IL-17A, IL-17F, IL-22 and
TNF-a,14,15 these TH17 cells have been implicated in the
pathogenesis of autoimmune disorders.16al characteristics.
COPD n Z 39 CS
66  10 6
30/9 9/
45  26 3
1.57  0.7 2
56.7  23.1 99
2.9  1.02 3
82.5  20.3 98
53  13.8 80
rrent smokers; HS Z Healthy subBased on the hypothesis of the autoimmune component
in COPD and the important role of Th17 cells in the devel-
opment of autoimmune disorders, we studied the distribu-
tion of this effectors subpopulation in peripheral blood (PB)
of COPD patients, current smokers without COPD (CS) and
healthy subjects who never smoked (HS).Patients and methodsPatients
The study was carried out at the National Institute of
respiratory diseases, in Mexico City. Included were 39
consecutive patients with a previous COPD diagnosis at
least 1 year prior to the study, 14 CS who wanted to stop
smoking, and 15 HS. The protocol was authorized by the
ethics and research committees of the institution and all
subjects signed a letter of informed consent. Patients
belonged to a cohort of subjects with COPD who were
evaluated in a clinically stable, exacerbation-free period 6
weeks prior. They had history of tobacco smoking of at least
10 pack/years.
Subjects who met the criteria for COPD but had a known
alternative respiratory disorder (such as bronchiectasis or
asthma) were excluded. The CS, was recruited when they
attended the smoking cessation program of the Institute.
Both CS and HS had normal lung function tests. Subjects
from either group having additional comorbidities with
some autoimmune component such as type 1 diabetes
mellitus, or rheumatoid arthritis, among others, were
excluded as well.
Diagnosis of COPD
COPD diagnosis was established according to the history of
tobacco smoking, symptoms and pulmonary function tests
with FEV1/FVC post-bronchodilator lower than 70%,n Z 14 HS n Z 15 *p Value
4  7 68  6 0.4
5 8/7 0.2
0  26 e 0.35
.7  0.9 3.8  0.4 <0.0001
.5  18.7 109.8  12 <0.0001
.4  1 4.03  0.47 0.1
.2  17 107.7  11.3 0.002
.6  5.3 80.5  6.2 <0.0001
jects Values are expressed as mean and standard deviation.
Figure 1 Flow cytometry analysis of the Th17 subpopulations
in COPD patients, Current smokers and Healthy Subjects.
Representative dot plots showing ex vivo-detected CD4þ T cells
producing IL-17A in human peripheral blood lymphocytes from
healthy subjects (HS), current smokers (CS) and patients with
chronic obstructive pulmonary disease (COPD).
1650 M.I. Vargas-Rojas et al.according to the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) guidelines.17
Spirometry
Subjects were submitted to spirometry both pre- and
postbronchodilator following the procedures recommended
by the American Thoracic Society and the European
Respiratory Society (ATS/ERS)18 with a dry rolling-seal
volume spirometer (Sensormedics; Yorbalinda, California)
and using Perez-Padilla reference equations.19
Analysis of the TCD4D cell subpopulations in
mononuclear cells by flow cytometry
Peripheral blood mononuclear cells (PBMC) were isolated
by density gradient centrifugation on Lynphoprep (Axis-
Shield PoC AS, Oslo, Norway). In order to analyze the
distribution of different T cell subpopulations (Th1, Th2,
Th17 and Tregs, defined as CD3þCD4þ plus INF-gþ, IL-4þ, IL-
17Aþ and FOXP3þ respectively) we used conventional stains
with anti-CD3-APC, CD4-Cy5 (BD Biosciences). For the
Intracellular staining we used anti-IFNg PE-Cy7, anti-IL-4-
PE (BD Biosciences), anti-IL-17A-PE and anti-FOXP3-FITC
(eBioscience). BD Cytofix/Cytoperm reagent (BD Biosci-
ences) was used for cell permeabilization. The specificity of
staining by Abs to target antigens should be verified by
establishing the amount of non-specific antibody binding,
isotype controls are direct immunofluorescence reagents
used for measuring background fluorescence from cellular
autofluorescence and nonantigen-specific binding. A total
of 50,000 events were recorded for each sample and
analyzed with the FlowJo software (BD Biosciences). The T
cell subsets were expressed as percent of CD3þCD4þ.
Statistical analysis
Variables with normal distribution were expressed as mean
and standard deviation, whereas differences were tested
with impaired t-test and ANOVA when necessary. T cell
subsets were expressed as median and range and differ-
ences in distribution of T cell subsets were analyzed with
KruskaleWallis analysis. For between-group differences,
ManneWithney U test was used. Spearman’s correlation
tests were used to analyze the relationships between
pulmonary function and T cell subsets. In order to identify
some potential associations between Th2 and Th17 cells
and airflow limitation, logistic regression analysis was per-
formed. SPSS version 16 software was used.
Results
Demographic and clinical characteristics are summarized in
Table 1. No differences in age were found between groups.
The mean cumulative tobacco consumption for COPD
patients was 45  26 pack-years and 30  26 pack-years for
CS group, respectively (p Z 0.35). According to the GOLD
classification, a significant proportion of patients (42%)
were in stage III; whereas only 5% were in stage IV. Seventy
three percent of patients with COPD were on inhaledsteroids and long-acting bronchodilators. None of the
subjects was using oral steroids.
A plot of the flow cytometry analysis of the Th17
subpopulations in COPD, CS and HS is shown on Fig. 1.
Significant differences were found both in subjects with
COPD [median 9.7% (range 0.8e22.5%)] in comparison with
CS [median 2.8% (range 0.8e10.6%)] and HS [median 0.6%
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Figure 2 Comparison of the T-cell subpopulations between COPD patients, Current smokers and Healthy Subjects. Distribution of
T-cell subpopulations (Th1, Th2, TH17 and Treg) in peripheral blood (PB) of healthy subjects (HS), current smokers (CS) and
patients with chronic obstructive pulmonary disease (COPD). In general, higher percentages of Th1, Th2, but in particular Treg and
Th17 subsets, were observed in PB of CS and patients with COPD.
Increase of Th17 cells in peripheral blood 1651(range 0.4e1%) p < 0.0001] (Fig. 2 and Table 2). In addition,
a higher proportion of Th2 cells was found in COPD [median
3.2% (range 0.8e13.6%)] in comparison to CS [median 1.4%
(range 0.6e4.2%), p Z 0.01] and HS [median 1.3% (range
0.9e1.6%) p Z 0.005]. The proportion of Treg was signifi-
cantly lower in HS in comparison with COPD [median 5.2%
(range: 4.1e6.6% vs. 8.8% range 1.7e19.2%) respectively,
p Z 0.006]. Interestingly, Th1 cells percent only was
significantly higher in CS in comparison with HS but not with
COPD patients.
No association was found between Th17 cells and GOLD
stage or between the uses of inhaled steroids. Interesting
inverse correlations were found between Th17 with FEV1%p
(r Z 0.57, p < 0.0001) (Fig. 3A) and with FEV1/FVC
(r Z 0.60, p < 0.0001) (Fig. 3B) and Th2 cells with both
FEV1%p and FEV1/FVC (r Z 0.44, and r Z 0.49,
respectively p < 0.0001 for both comparations). A corre-
lation was found between Th17 with Treg (r Z 0.40,
p Z 0.001) and Th1 (r Z 0.48, p < 0.0001).
In the multivariate regression analysis we found that the
increase of Th17 predicted the presence [OR 1.76 (CI 95%
1.25e2.49, p Z 0.001)] and severity of airflow limitation
[OR 1.13 (CI 95% 1.02e1.25, pZ 0.02)]. Similar results were
found with Th2 cells and the airflow limitation [OR 3.8 (CI
95% 1.55e9.3) p Z 0.003 and OR 1.73 (CI 95% 1.15e2.61)Table 2 T cell subsets in peripheral blood.
COPD n Z 39 Median(range) CS n Z 14
Subpopulation
Th1% 2.5 (0.9e14) 3.6 (1e9.2
Th2% 3.2 (0.8e13.6)Oˆx 1.4 (0.6e4
Th17% 9.7 (0.8e22.5)** 2.8 (0.8e1
Treg % 8.8 (1.7e19.2)# 8.7 (5.3e1
Definition of abbreviations: COPDZ Patients with COPD, CSZ Current
are expressed as median and range.
Th1: z CS versus HS, pZ 0.01; Th2: Oˆ COPD versus CS, pZ 0.01; xCOPD
Tregs: #COPD versus HS, p Z 0.006.p Z 0.009, for presence and severity respectively] (Table
3). These associations were not found whit FEV1 > 50%p.Discussion
The most relevant finding of this study is the significant
increase of Th17 cells in PB of COPD patients. To the best of
our knowledge, this is the first study in humans that
demonstrates polarization of Th17 cells and their balance
with Th1/Th2 and Treg subpopulations in COPD and CS.
Additional findings of this study are that Th17 and Treg cells
showed a progressive increase from HS to CS and COPD
group. Th17 subset also showed a negative correlation with
FEV1 and FEV1/FVC, the greater the amount of Th17 cells,
the poorer the airflow limitation.
In general, it is well accepted that Th1 cells contribute
largely, but not exclusively, to the inflammatory cascade of
events related to the pathogenesis of COPD.8,9 Previous
studies demonstrated that Th2 cells may be important in the
inflammatory response of the disease.20e22 The correlation
reported in our results betweenTh2 cells and FEV1%p suggests
an important participation of this cell population in the
process of bronchial hyperresponsiveness. More recently,
a third subpopulation of CD4þ Tcells has emerged as a potentMedian(range) HS n Z 15 Median(range)
*p-value
)z 1 (0.6e1.4) <0.0001
.2) 1.3 (0.9e1.6) 0.001
0.6) 0.6 (0.4e1) <0.0001
0.9)* 5.2 (4.1e6.6) 0.009
smokers; HSZ Healthy subjects. * KruskaleWallis analysis Values
versus HS, pZ 0.005; Th17: **COPD versus CS and HS, p < 0.0001;
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Figure 3 Association between Th17 cells and lung function. Spearman’s rank correlation between percentage of Th17 cells with
(A) FEV1%p and with (B) FEV1/FVC.
1652 M.I. Vargas-Rojas et al.proinflammatory potentially involved in the genesis of auto-
immune disease. These cells, designated as Th17 because of
their capacity for producing IL-17A and IL-17F cytokines not
produced by the classical CD4þ effectors T cell, Th1 and Th2,
are also known to produce IL-6, IL-22, GM-CSF, TNF-a and to
express receptors for both IL-18 and IL-23.23,24
The interesting issue of this study is that Th17 polari-
zation in patients suggests their involvement in the
inflammatory process of COPD. There are at least two
characteristics that may point to them as an additional
protagonist in this disease. The first is that IL-17 acts
directly on epithelial cells, airway fibroblasts and smooth
muscle cells to induce the secretion of neutrophil-
recruiting chemokines,25 which are potent inducers of IL-6
production by bronchial epithelial cells and fibroblasts.26
Both cytokines are capable of stimulating mucus produc-
tion by inducing Muc5AC and Muc5B genes.27 This fact may
contribute to symptoms such as cough and phlegm and
tissue injury in subjects with chronic bronchitis and
emphysema. Second, the lack of regulation in the response
of Th17 cells leads to the perpetuation of an inflammatory
response. Furthermore, research has demonstrated the
involvement of this subset in the development of autoim-
mune diseases.28,29
Autoimmunity in the pathogenesis of COPD has been
a triggering hypothesis since the pioneer paper by Agustı´
and colleagues.4 That opinion received little attention until
the study by Di Stefano et al.30 that provoked comments
suggesting that COPD is a disease produced, at least in part,
by antigens (self or self-modified) from the lung (auto-
immune), secondary to smoking.31 More recently, Cosio
et al.32 proposed that the mechanisms leading to COPD can
be contemplated in three progressive steps where the last
one (corresponding to patients in stage GOLD III-IV)
depends on the previous ones. Whereas step 1 isTable 3 Association of Th17 and Th2 cells with the presence o
Variable FEV1/FVC  0.70 p val
Th17 OR 1.76 (CI 95% 1.25e2.49) 0.001
Th2 OR 3.8 (CI 95%1.55e9.3) 0.003
Regression analysis adjusted by age and gender.explained by the innate immune response and the “danger”
hypothesis of Matzinger,33 step 2 depends on the ability of
dendritic cells to stimulate the immunoregulatory mecha-
nisms of CD 4þ T cells and, step 3, among others, on the
failure of the immune regulation.
In the context of our findings, the association of Th17
with FEV1 suggests a role for these cells in the genesis of the
airflow limitation. The interplay between Th17, Th1, Th2
and Treg cells has been previously addressed by Awasthi
et al.34 who postulated that if the loss of Th1 dominant
cytokine, IFN-g, does not prevent the development of
autoimmunity,35 then the possibility of involvement of
other Th subsets different from Th1 cells in the induction of
autoimmunity must explain autoimmune diseases. This new
subset of Th cells that predominantly produce IL-17 and
induce autoimmunity may be a key cell type involved in
orchestrating the transition between steps 2 and 3,
according to the hypothesis by Cosio et al.32
Activation of T cells by antigens associated with ciga-
rette smoke causes lung damage.36 Increased expression of
STAT4 and INF-g in patients with COPD and the presence of
oligoclonal CD4þ T cells in lungs of these patients11 suggest
that the accumulation of these is due to the persistent
antigenic stimulus of cigarette smoke. Furthermore,
previous studies reported an increase in Treg cells in
smokers with or without COPD. This increase is related to
a long-time exposure to cigarette smoke but not with
airway obstruction.37 Our results show a clear increase in
pro-inflammatory cells (Th1 and Th17) and Tregs in CS,
suggesting the involvement of a mechanism of peripheral
tolerance in the modulation of the inflammatory response
caused by cigarette smoke.
The presence of Th17 cells may play a role in the
development of COPD with increased production of IL-6 by
dendritic cells that promote differentiation of this subset off airflow limitation.
ue FEV1  50 p% p value
OR 1.13 (CI 95% 1.02e1.25) 0.02
OR 1.73 (CI 95% 1.15e2.61) 0.009
Figure 4 Hypothetical schema of the Loss of balance of CD4þ T cells with cigarette smoke exposure. In healthy subjects CD4þ T
cells are in homeostasis. After noxious stimuli such as cigarette smoke, two different scenarios (A or B) may occur. The solid arrow
at the bottom shows the time in years. In the inflammatory race (A), smoking promotes the differentiation of naı¨ve T cells into T
cells with a proinflammatory profile (Th1 and Th17), with subsequent increase of Treg cells. This inflammatory state may remain
unchanged during the lifetime of smokers, although this has also been associated with many different diseases and cancers.
Increase of Treg cells is assumed to be the mechanism by which the inflammatory response is contained. In the autoimmunity race
(B) during early years, the immunoregulatory balance in susceptible subjects is retained (dashed lines from the Tregs cells) at the
expense of a large number of signals. However, despite the proliferation of Tregs, the harmful stimulus from smoking can produce
COPD if it overwhelms the regulatory mechanisms of peripheral tolerance induced either by the resistance of the effector T cells to
be regulated or by an intrinsic fail in the function of Treg cells leading to uncontrolled proliferation of Th17 cells involved in
autoimmune inflammatory processes.
Increase of Th17 cells in peripheral blood 1653effectors T cells. It is interesting, according to our results,
that the loss of balance in the CD4þ T cells by an increase in
Th cells is associated with an increase in Treg cell pop-
ulation, suggesting an attempt to control the inflammatory
response. However, in susceptible individuals this mecha-
nism of peripheral tolerance fails or these individuals are
overwhelmed by the persistence of an antigenic stimulus.
Based on our results, a hypothetical chain of events is
shown in Fig. 4. The schema assumes a cascade of signals,
mediators and events that are not mentioned.
The main limitation of our study is that the results come
from measurements obtained only from peripheral blood
cells. Ideally, samples should be taken from the site where
the inflammatory events are occurring either from the
alveolar spaces or lung tissue through bronchoalveolar
lavage and/or biopsies. In this sense, more research is
needed since the available literature on the subject is
scanty. However, it is important to consider that the
increase of Th17 cells in peripheral blood is present in COPD,
and complements previous studies reporting IL-17 in situ.38
Conclusions
In summary, our results provoke a discussion on the possible
antagonism and conciliation among Th1, Th2, Th17 and
Treg subsets and support the emerging hypothesis of
autoimmunity in the pathogenesis of COPD associated with
cigarette smoking. Future research should focus on the
effect of cigarette smoke on the subsets of CD4þ T cells as
a trigger for the inflammatory response that can cause the
development of COPD in susceptible individuals.Authors’ contributions
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